Nitipol Ken Srimongkolpithak - Publications
Affiliations: | National Center for Genetic Engineering and Biotechnology, Thailand |
Area:
medicinal chemistryYear | Citation | Score | |||
---|---|---|---|---|---|
2015 | Curry E, Green I, Chapman-Rothe N, Shamsaei E, Kandil S, Cherblanc FL, Payne L, Bell E, Ganesh T, Srimongkolpithak N, Caron J, Li F, Uren AG, Snyder JP, Vedadi M, et al. Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells. Clinical Epigenetics. 7: 84. PMID 26300989 DOI: 10.1016/S0959-8049(14)70680-X | 0.53 | |||
2014 | Srimongkolpithak N, Sundriyal S, Li F, Vedadi M, Fuchter MJ. Identification of 2,4-diamino-6,7-dimethoxyquinoline derivatives as G9a inhibitorsâ Electronic supplementary information (ESI) available. See DOI: 10.1039/c4md00274a. Medchemcomm. 5: 1821-1828. PMID 25750706 DOI: 10.1039/C4Md00274A | 0.545 | |||
2014 | Sundriyal S, Malmquist NA, Caron J, Blundell S, Liu F, Chen X, Srimongkolpithak N, Jin J, Charman SA, Scherf A, Fuchter MJ. Development of diaminoquinazoline histone lysine methyltransferase inhibitors as potent blood-stage antimalarial compounds. Chemmedchem. 9: 2360-73. PMID 25044750 DOI: 10.1002/Cmdc.201402098 | 0.563 | |||
2013 | Cherblanc FL, Davidson RW, Di Fruscia P, Srimongkolpithak N, Fuchter MJ. Perspectives on natural product epigenetic modulators in chemical biology and medicine. Natural Product Reports. 30: 605-24. PMID 23396528 DOI: 10.1039/C3Np20097C | 0.508 | |||
Show low-probability matches. |